179 related articles for article (PubMed ID: 22745940)
1. Effect of the cytochrome P450 2D6*10 allele on risperidone metabolism in Japanese psychiatric patients.
Suzuki Y; Fukui N; Tsuneyama N; Watanabe J; Ono S; Sugai T; Saito M; Inoue Y; Someya T
Hum Psychopharmacol; 2012 Jan; 27(1):43-6. PubMed ID: 22745940
[TBL] [Abstract][Full Text] [Related]
2. Impact of the ABCB1 gene polymorphism on plasma 9-hydroxyrisperidone and active moiety levels in Japanese patients with schizophrenia.
Suzuki Y; Tsuneyama N; Fukui N; Sugai T; Watanabe J; Ono S; Saito M; Someya T
J Clin Psychopharmacol; 2013 Jun; 33(3):411-4. PubMed ID: 23609388
[TBL] [Abstract][Full Text] [Related]
3. Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients.
Kang RH; Jung SM; Kim KA; Lee DK; Cho HK; Jung BJ; Kim YK; Kim SH; Han C; Lee MS; Park JY
J Clin Psychopharmacol; 2009 Jun; 29(3):272-7. PubMed ID: 19440082
[TBL] [Abstract][Full Text] [Related]
4. Risperidone plasma levels, clinical response and side-effects.
Riedel M; Schwarz MJ; Strassnig M; Spellmann I; Müller-Arends A; Weber K; Zach J; Müller N; Möller HJ
Eur Arch Psychiatry Clin Neurosci; 2005 Aug; 255(4):261-8. PubMed ID: 15565299
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.
Scordo MG; Spina E; Facciolà G; Avenoso A; Johansson I; Dahl ML
Psychopharmacology (Berl); 1999 Dec; 147(3):300-5. PubMed ID: 10639689
[TBL] [Abstract][Full Text] [Related]
6. ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety.
Gunes A; Spina E; Dahl ML; Scordo MG
Ther Drug Monit; 2008 Oct; 30(5):628-33. PubMed ID: 18708991
[TBL] [Abstract][Full Text] [Related]
7. Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia.
Yasui-Furukori N; Mihara K; Kondo T; Kubota T; Iga T; Takarada Y; De Vries R; Kaneko S; Tateishi T
J Clin Pharmacol; 2003 Feb; 43(2):122-7. PubMed ID: 12616663
[TBL] [Abstract][Full Text] [Related]
8. Physiologically Based Pharmacokinetic Modelling to Describe the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone According to Cytochrome P450 2D6 Phenotypes.
Kneller LA; Abad-Santos F; Hempel G
Clin Pharmacokinet; 2020 Jan; 59(1):51-65. PubMed ID: 31359271
[TBL] [Abstract][Full Text] [Related]
9. The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone.
Jovanović N; Božina N; Lovrić M; Medved V; Jakovljević M; Peleš AM
Eur J Clin Pharmacol; 2010 Nov; 66(11):1109-17. PubMed ID: 20563569
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P450-mediated interaction between perazine and risperidone: implications for antipsychotic polypharmacy.
Paulzen M; Haen E; Hiemke C; Stegmann B; Lammertz SE; Gründer G; Schoretsanitis G
Br J Clin Pharmacol; 2017 Aug; 83(8):1668-1675. PubMed ID: 28160505
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients - thinking of clinically relevant CYP2D6 interactions.
Paulzen M; Haen E; Gründer G; Lammertz SE; Stegmann B; Schruers KR; Walther S; Schoretsanitis G
J Psychopharmacol; 2016 Aug; 30(8):803-9. PubMed ID: 27251417
[TBL] [Abstract][Full Text] [Related]
12. Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia.
Mihara K; Kondo T; Yasui-Furukori N; Suzuki A; Ishida M; Ono S; Kubota T; Iga T; Takarada Y; de Vries R; Kaneko S
Ther Drug Monit; 2003 Jun; 25(3):287-93. PubMed ID: 12766554
[TBL] [Abstract][Full Text] [Related]
13. Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.
Kakihara S; Yoshimura R; Shinkai K; Matsumoto C; Goto M; Kaji K; Yamada Y; Ueda N; Ohmori O; Nakamura J
Int Clin Psychopharmacol; 2005 Mar; 20(2):71-8. PubMed ID: 15729081
[TBL] [Abstract][Full Text] [Related]
14. Impact of CYP2D6 Polymorphism on Steady-State Plasma Levels of Risperidone and 9-Hydroxyrisperidone in Thai Children and Adolescents with Autism Spectrum Disorder.
Vanwong N; Ngamsamut N; Medhasi S; Puangpetch A; Chamnanphon M; Tan-Kam T; Hongkaew Y; Limsila P; Sukasem C
J Child Adolesc Psychopharmacol; 2017 Mar; 27(2):185-191. PubMed ID: 26780783
[TBL] [Abstract][Full Text] [Related]
15. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A.
Bork JA; Rogers T; Wedlund PJ; de Leon J
J Clin Psychiatry; 1999 Jul; 60(7):469-76. PubMed ID: 10453802
[TBL] [Abstract][Full Text] [Related]
16. Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia.
Yagihashi T; Mizuno M; Chino B; Sato Y; Sakuma K; Takebayashi T; Takao T; Kosaki K
Hum Psychopharmacol; 2009 Jun; 24(4):301-8. PubMed ID: 19387994
[TBL] [Abstract][Full Text] [Related]
17. Body mass index (BMI) but not body weight is associated with changes in the metabolism of risperidone; A pharmacokinetics-based hypothesis.
Paulzen M; Haen E; Stegmann B; Hiemke C; Gründer G; Lammertz SE; Schoretsanitis G
Psychoneuroendocrinology; 2016 Nov; 73():9-15. PubMed ID: 27448523
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients.
Jung SM; Kim KA; Cho HK; Jung IG; Park PW; Byun WT; Park JY
Clin Pharmacol Ther; 2005 Nov; 78(5):520-8. PubMed ID: 16321618
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and bioequivalence evaluation of risperidone in healthy male subjects with different CYP2D6 genotypes.
Cho HY; Lee YB
Arch Pharm Res; 2006 Jun; 29(6):525-33. PubMed ID: 16833023
[TBL] [Abstract][Full Text] [Related]
20. Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia.
Wang L; Yu L; Zhang AP; Fang C; Du J; Gu NF; Qin SY; Feng GY; Li XW; Xing QH; He L
J Psychopharmacol; 2007 Nov; 21(8):837-42. PubMed ID: 17715206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]